Joint wear causes pain, stiffness and reduced mobility, and articular cartilage has very limited capacity to heal on its own. Patients are often presented with a range of options spanning symptom management, surgical repair and newer regenerative approaches. Understanding how these compare — in terms of mechanism, invasiveness and realistic expectations — is the most useful starting point when deciding which path to explore. This article places ChondroFiller in that broader context.

Traditional Cartilage Care

Established treatments for cartilage damage fall into two broad categories: surgical repair techniques and non-surgical symptomatic management.

On the surgical side, debridement (arthroscopic removal of loose or damaged tissue) can reduce mechanical symptoms in the short term but does not restore the cartilage surface. Microfracture — creating small perforations in the subchondral bone to stimulate a healing response — has been widely used for focal defects, though published evidence suggests that the fibrocartilage tissue it produces is structurally inferior to native hyaline cartilage and clinical benefits tend to diminish after two to three years. More involved procedures such as autologous chondrocyte implantation (ACI) or osteochondral grafting can achieve durable results in selected patients, but they require two-stage surgery, prolonged rehabilitation and carry greater procedural risk.

Non-surgical options include hyaluronic acid injections, which lubricate the joint and can ease symptoms, and platelet-rich plasma (PRP), which delivers growth factors to support the joint environment. These can be helpful for symptom management and biological support, but they do not replace lost cartilage. Stem cell therapy — typically delivered via bone marrow aspirate concentrate (BMAC) or micro-fragmented adipose tissue — introduces regenerative cells into the joint and forms part of more advanced protocols, though evidence is still maturing.

Each of these approaches sits at a different point on the spectrum from symptom management to structural repair. No single treatment is universally appropriate; patient age, defect size, joint alignment and activity level all influence which option is most likely to help.

What ChondroFiller Is — and Is Not

ChondroFiller is a CE-marked Class III medical device: an acellular, type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany. It is cell-free by design — its role is to fill a cartilage defect and provide a three-dimensional matrix into which the patient's own progenitor cells can migrate, differentiate and produce new tissue. The scaffold gradually resorbs over one to two years as endogenous repair progresses. Published clinical data, including IKDC scores improving by approximately 30 points at 12 to 36 months in the knee and MOCART imaging scores ranging from 70 to 87 indicating substantial defect fill, support its use across multiple joints. Across more than 19,000 units sold since 2013, the device has a complaint rate of around 0.06%, with no serious incidents reported.

ChondroFiller is not a cure for osteoarthritis and does not reverse established joint degeneration. Its evidence base applies to focal cartilage defects — typically up to around 6 cm² — in joints that remain stable and well aligned. Realistic expectations are essential.

Two Delivery Pathways: Injection and Surgery

The ChondroFiller scaffold can be delivered in two clinically distinct ways, and understanding the difference is important.

The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure. No theatre, no general anaesthetic and no incision are required. The scaffold is introduced directly into the joint, where it self-gels within three to five minutes. This pathway suits accessible lesions and smaller joints — including the thumb's trapeziometacarpal joint, where published case series (Corain et al., Cartilage, 2023) have demonstrated significant pain reduction and functional improvement in osteoarthritis. Recovery is simpler and shorter than any surgical option.

For larger, load-bearing defects — such as those in the knee, hip, shoulder or ankle — the Liquid Cartilage surgical protocol (also called the Lee Liquid Cartilage Protocol, or LLC Protocol) offers a more comprehensive approach. Liquid Cartilage is not a product; it is Professor Paul Lee's keyhole (arthroscopic) surgical technique that combines the ChondroFiller scaffold with biological adjuncts including platelet-rich fibrin, platelet-rich plasma and tranexamic acid, and optionally the patient's own mesenchymal stem cells from bone marrow aspirate concentrate or micro-fragmented adipose tissue. The procedure takes place in theatre under anaesthetic and is followed by a structured rehabilitation programme. Liquid Cartilage is genuine surgery — it is not an injection.

Choosing between the injection and the surgical protocol depends on defect size, joint location, load demands and patient factors. An experienced specialist assessment is necessary to determine which is appropriate.

Comparing ChondroFiller With Traditional Options

Against the backdrop of traditional care, ChondroFiller — whether delivered by injection or via the Liquid Cartilage surgical protocol — occupies a regenerative niche that older techniques do not fill. Debridement and microfracture address the joint mechanically but do not provide a structured scaffold for biological repair. Hyaluronic acid and PRP injections support the joint environment but are not regenerative scaffolds. ACI achieves durable structural repair in selected patients but requires two surgical procedures, extensive rehabilitation and substantial cost.

ChondroFiller's single-stage application, strong safety profile and early evidence of hyaline-like tissue regeneration make it a notable addition to the treatment pathway. However, it is technique-sensitive: the published literature consistently shows that outcomes are influenced by how carefully the procedure is performed and by whom. It is not a straightforward filler applied to any worn surface — appropriate preparation of the defect, patient selection and post-procedure management all matter.

In terms of recovery, the injection pathway typically involves a shorter and less disruptive course than any surgical approach. The Liquid Cartilage surgical protocol carries the usual risks of keyhole surgery — infection, stiffness, anaesthetic risk — alongside the specific consideration that the scaffold must gel correctly under controlled conditions. Unlike microfracture, neither delivery pathway breaches the subchondral bone plate, which preserves future surgical options if they are ever needed.

How ChondroFiller Fits Into a Personalised Treatment Plan

Cartilage care is not a linear ladder from simple to complex. A patient with a focal, accessible cartilage lesion and a stable joint may be well served by the ChondroFiller injection alone. A patient with a larger defect in a load-bearing joint, or one where biological augmentation is likely to improve outcomes, may be better served by the Liquid Cartilage surgical protocol. Many patients will already have trialled physiotherapy, anti-inflammatory medication or basic injections before arriving at the decision stage for a regenerative intervention.

The cartilage care landscape has changed considerably in recent years, and no single comparator tells the whole story. What matters most is an honest assessment of the specific defect, the patient's goals and the realistic range of outcomes for each available option.

Expert Guidance at London Cartilage Clinic

At the London Cartilage Clinic, Professor Paul Lee — who developed the Liquid Cartilage surgical protocol — provides specialist assessment for patients with cartilage and joint preservation concerns. The clinic offers access to both the ChondroFiller injection pathway and the Liquid Cartilage surgical protocol, with personalised guidance and realistic expectations. If you would like to explore which approach may be appropriate for your situation, a consultation is the right starting point.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.